|本期目录/Table of Contents|

[1]曹 参 李 靖 吴勤研.吉非替尼联合化疗方案应用于晚期肺腺癌患者的临床疗效及安全性分析[J].中华肺部疾病杂志,2020,(04):484-487.[doi:10.3877/cma.j.issn.1674-6902.2020.04.011]
 Cao Shen,Li Jing,Wu Qinyan..Clinical efficacy and safety of gefitinib combined with chemotherapy in treatment of advanced lung adenocarcinoma[J].,2020,(04):484-487.[doi:10.3877/cma.j.issn.1674-6902.2020.04.011]
点击复制

吉非替尼联合化疗方案应用于晚期肺腺癌患者的临床疗效及安全性分析(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2020年04期
页码:
484-487
栏目:
论著
出版日期:
2020-08-20

文章信息/Info

Title:
Clinical efficacy and safety of gefitinib combined with chemotherapy in treatment of advanced lung adenocarcinoma
作者:
曹 参 李 靖 吴勤研
210000 南京,东部战区总医院药品科
Author(s):
Cao Shen Li Jing Wu Qinyan.
Pharmaceutical Department, General Hospital of Eastern Theater Command, Nanjing 210000, China
Corresponding author
关键词:
肺腺癌 吉非替尼 联合化疗 临床疗效 安全性
Keywords:
Lung adenocarcinoma Gefitinib Combined chemotherapy Clinical efficacy Safety
分类号:
R563
DOI:
10.3877/cma.j.issn.1674-6902.2020.04.011
摘要:
目的 分析吉非替尼(gefitinib)联合化学治疗方案应用于晚期肺腺癌患者所产生的临床疗效及安全性。方法 选取2016年10月至2018年6月在我院收治的80例晚期肺腺癌,以随机数字表作为分组工具,分为研究组38例和对照组42例,研究组给予吉非替尼联合化疗方案治疗,对照组给予厄洛替尼联合化疗方案治疗。比较两组患者的临床疗效、肿瘤大小变化情况和不良反应发生情况。结果 研究组总控制率为73.7%,高于对照组的50.0%,差异有统计学意义(P<0.05); 研究组肿瘤增大所占比例为13.2%,低于对照组的35.0%,差异有统计学意义(P<0.05); 研究组骨髓抑制、肝损害的发生率分别为47.4%、31.6%,低于对照组的74.0%、65.0%,差异有统计学意义(P<0.05)。结论 吉非替尼应用于晚期肺腺癌患者,能协同提高抗癌效果,且能减少躯体不适反应的发生率,亦能控制癌细胞增殖,可考虑将其作为抗癌方案之一。
Abstract:
Objective To analyze the clinical efficacy and safety of gefitinib combined with chemotherapy in the treatment of advanced lung adenocarcinoma. Methods Eighty patients with advanced lung adenocarcinoma admitted to our hospital from October 2016 to June 2018 were selected for this study. The patients were divided randomly into a study group(n=38)and a control group(n=42). The study group received treatment regimen of gefitinib combined with chemotherapy, while the control group received treatment regimen of erlotinib combined with chemotherapy. The clinical efficacy, tumor size changes and incidence of adverse reactions were compared between the two groups. Results The total control rate of the study group was 73.7%, higher than that of the control group(50.0%), with statistical significant difference between the two groups(P<0.05). The proportion of tumor enlargement in the study group was 13.2%, lower than that of the control group(35.0%), with statistical significant difference between the two groups(P<0.05). The incidences of bone marrow depression and liver damage in the study group were 47.4% and 31.6%, respectively, which were lower than those of the control group(74.0% and 65.0%, respectively), with statistical significant difference between the two groups(P<0.05). Conclusion Gefitinib can improve the anticancer effect of advanced lung adenocarcinoma, reduce the occurrence of somatic discomfort, and control the proliferation of cancer cells. Therefore, gefitinib may be considered as an anticancer regimen.

参考文献/References:

1 任成山, 王关嵩, 钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
2 贺雪黛, 李 烜. 参苓白术散加减联合吉非替尼治疗中晚期肺腺癌21例临床研究[J]. 江苏中医药, 2017, 49(4): 24-26.
3 Zhao W, Zhao H, Wang H, et al. Combined effects of pemetrexed disodium and gefitinib on radiation sensitivity in human lung adenocarcinoma cells[J]. Acta Univ Med Nanjing, 2017, 9(4): 867-870.
4 Yang L, Fan JH, Liu LL, et al. Comparison of gefitinib and platinum-based chemotherapy and only platinum-based chemotherapy to treat lung adenocarcinoma[J]. J Biol Regul Homeost Agents, 2018, 32(3): 613.
5 Urata Y, Katakami N, Morita S, et al. Randomized Phase Ⅲ Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L[J]. J Clin Oncol, 2016, 34(27): 3248-3257.
6 张洁霞, 蔡 迪, 李时悦, 等. 非小细胞肺癌脑转移厄洛替尼和吉非替尼治疗临床比较[J]. 中华肿瘤防治杂志, 2015, 22(4): 285-288.
7 Yang L, Pang R. Clinical Observation of Fuzheng Kangai Prescription Combined with Gefitinib in Treating for Advanced Lung Adenocarcinoma[J]. Acta Chinese Med, 2018, 9(5): 236-240.
8 Patel N, Wu P, Zhang H. Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation[J]. Cancer Manag Res, 2017, 9: 243-248.
9 王起龙, 李 敏, 胡成平. 吉非替尼可能通过EGFR启动子甲基化诱导肺腺癌细胞继发性耐药[J]. 中国肺癌杂志, 2015, 18(4): 193-198.
10 Kumar R, Dubashi B, Kayal S, et al. Study of gefitinib maintenance in unselected patients with metastatic primary lung adenocarcinoma: A descriptive study[J]. Indian J Cancer, 2017, 54(1): 188.
11 方 陈, 周 曦, 王永生, 等. MiR-214对人肺腺癌细胞PC9增殖及凋亡的研究[J]. 中国肿瘤, 2015, 24(10): 860-863.
12 Duan H, Peng Y, Cui H, et al. Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report:[J]. Oncotargets & Therapy, 2018, 11: 2303-2309.
13 潘 莹, 黄思超, 王 霞, 等. NF-κB亚单位p50/p65激活促进肺腺癌H1650细胞吉非替尼耐药[J]. 南方医科大学学报, 2018, 38(5): 584-590.
14 Liu Y, Jiang H, Zhou H, et al. Lentivirus-mediated silencing of HOTAIR lncRNA restores gefitinib sensitivity by activating Bax/Caspase-3 and suppressing TGF-α/EGFR signaling in lung adenocarcinoma:[J]. Oncol Lett, 2018, 15(3): 2829-2838.
15 Hsia T, Tu C, Chen H, et al. P2.03-003 Cost Effectiveness of Gefitinib for Lung Adenocarcinoma Patients with Mutant Epidermal Growth Factor Receptor[J]. J Thoracic Oncol, 2017, 12(11): S2128.
16 Bjaanæs MM, Fleischer T, Halvorsen AR, et al. Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis.[J]. Molecul Oncol, 2016, 10(2): 330-343.
17 田 涛, 傅 潇, 武惠丽, 等. 吉非替尼联合化疗治疗靶向治疗失败的EGFR T790M野生型晚期肺腺癌的疗效观察[J]. 现代肿瘤医学, 2018, 26(22): 3582-3585.
18 朱亚宁, 张 鹏, 张 丹, 等. 评估吉非替尼交替化疗对比化疗治疗Ⅳ期非小细胞肺癌的疗效及安全性[J]. 中国医院药学杂志, 2016, 36(6): 480-484.
19 韩 伟, 邝先奎, 黄 堃, 等. 顺铂联合培美曲塞及吉非替尼序贯化疗治疗晚期肺腺癌疗效观察[J]. 中华实用诊断与治疗杂志, 2016, 30(3): 304-306.
20 罗 莉, 刘玉荣. 三维适形放疗联合同步吉非替尼化疗对肺癌患者细胞因子CSF、TNF、IL-2的影响[J]. 临床和实验医学杂志, 2016, 15(9): 865-868.
21 曹云堡, 胡 强. 培美曲塞联合固本消癥方治疗吉非替尼或二线化疗失败后老年肺腺癌的疗效及对生活质量的影响[J]. 现代中西医结合杂志, 2018, 27(27): 3029-3032.
22 江冠铭, 贾 筠, 谭钦全, 等. 化疗交替吉非替尼治疗表皮生长因子受体突变阳性晚期非小细胞肺癌的效果[J]. 广东医学, 2015, 6(11): 1757-1760.
23 徐晓鸿, 陈家斌, 夏银稳, 等. 沙利度胺联合吉非替尼新辅助化疗对非小细胞肺癌的临床价值[J]. 昆明医科大学学报, 2016, 37(1): 65-68.
24 吴辉塔, 王 馨, 郭艺芳, 等. 晚期肺腺癌EMT和EGFR突变状态的关系及其对吉非替尼治疗疗效的影响[J]. 癌症进展, 2016, 14(8): 757-760, 763.
25 胡作为, 赵 霞, 关江锋, 等. 吉非替尼联合DC-CIK细胞治疗晚期肺腺癌的临床疗效观察[J]. 中国医师杂志, 2016, 18(1): 56-59, 62.
26 娄娜娜, 杨衿记, 严红虹, 等. 吉非替尼与紫杉醇联合卡铂治疗晚期肺腺癌患者的效果分析[J]. 中华医学杂志, 2014, 94(30): 2337-2341.
27 陈文福. AC方案联合吉非替尼序贯治疗EGFR基因敏感突变的肺腺癌患者的临床疗效观察[J]. 实用癌症杂志, 2018, 33(10): 1651-1654, 1658.
28 赵 峰, 苗怡然, 曹生亚. 吉非替尼对EGFR敏感突变肺腺癌脑转移患者的预后影响[J]. 肿瘤学杂志, 2018, 24(3): 221-225.
29 程小珍, 毛山山, 谢宗宙, 等. 吉非替尼对晚期肺癌患者PD-L1、PD-1及Th1、Th17相关指标影响研究[J]. 陕西医学杂志, 2017, 46(7): 945-947.
30 徐 姝, 冯继锋, 林 勇. microRNA-200c 预测肺腺癌患者对吉非替尼的敏感性及其机制[J]. 现代肿瘤医学, 2016, 24(24): 3924-3926.
31 刘雨桃, 石远凯, 胡兴胜, 等. 吉非替尼治疗EGFR基因突变状态不明的青年晚期肺腺癌疗效分析[J]. 中国肺癌杂志, 2014, 17(5): 401-405.

备注/Memo

备注/Memo:
基金项目: 江苏省药学会科研立项(A201707)
通信作者: 李 靖, Email: 773913218@qq.com
更新日期/Last Update: 2020-08-20